F. Dachy
YOU?
Author Swipe
View article: LATE EFFECTS AFTER TREATMENT OF HODGKIN LYMPHOMA, A SINGLE CENTRE EXPERIENCE
LATE EFFECTS AFTER TREATMENT OF HODGKIN LYMPHOMA, A SINGLE CENTRE EXPERIENCE Open
Introduction: Classical Hodgkin Lymphoma (cHL) has an incredibly high survival rate, exceeding 80% at 10 years. Continuous improvement in treatment strategies led to an increased number of survivors in the community. Most common complicati…
View article: P1332: PROMISING OUTCOME OF PATIENTS OLDER THAN 70 YEARS WHO UNDERWENT PERIPHERAL BLOOD HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR ACUTE MYELOID LEUKEMIA OR HIGH RISK MYELODYSPLASTIC SYNDROME
P1332: PROMISING OUTCOME OF PATIENTS OLDER THAN 70 YEARS WHO UNDERWENT PERIPHERAL BLOOD HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR ACUTE MYELOID LEUKEMIA OR HIGH RISK MYELODYSPLASTIC SYNDROME Open
Background: Allogeneic stem cell transplantation is a curative option of patients older than 60 years of age with AML and high risk MDS. In this situation, the development of haploidentical transplantation (Haplo-SCT) using post transplant…
View article: P1329: POST-TRANSPLANT CYCLOPHOSPHAMIDE (PT-CY) VERSUS ANTITHYMOCYTE GLOBULIN (ATG) AS GVHD PROPHYLAXIS FOR MATCHED UNRELATED HEMATOPOIETIC STEM CELL TRANSPLANTATION.
P1329: POST-TRANSPLANT CYCLOPHOSPHAMIDE (PT-CY) VERSUS ANTITHYMOCYTE GLOBULIN (ATG) AS GVHD PROPHYLAXIS FOR MATCHED UNRELATED HEMATOPOIETIC STEM CELL TRANSPLANTATION. Open
Background: In recent years, post-transplant cyclophosphamide (PT-Cy) has become an essential component for GVHD prophylaxis in T-cell replete haploidentical (HRD) stem cell transplantation. It is now being evaluated in unrelated donor (UD…